Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis.
作者信息
van Leeuwen Jolijn R, Popov Tamara, Obergfell Achim, Rabelink Ton J, Teng Y K Onno
机构信息
Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden, the Netherlands.
Vifor Pharma Ltd, Glattbrugg, Switzerland.
出版信息
Biologics. 2023 Jan 25;17:11-14. doi: 10.2147/BTT.S394843. eCollection 2023.
Abstract
摘要
相似文献
1
Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis.在抗中性粒细胞胞浆抗体相关性血管炎早期准入项目中阿伐可泮安全性和耐受性的初步评估
Biologics. 2023 Jan 25;17:11-14. doi: 10.2147/BTT.S394843. eCollection 2023.
2
Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".《阿伐可泮治疗抗中性粒细胞胞浆抗体相关性血管炎》的期刊俱乐部评论
ACR Open Rheumatol. 2022 Jul;4(7):558-561. doi: 10.1002/acr2.11412. Epub 2022 Feb 15.
3
Avacopan in the treatment of ANCA-associated vasculitis.阿伐考潘治疗抗中性粒细胞胞质抗体相关性血管炎。
Expert Opin Investig Drugs. 2018 May;27(5):491-496. doi: 10.1080/13543784.2018.1472234. Epub 2018 May 8.
4
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.在接受利妥昔单抗或环磷酰胺/硫唑嘌呤联合治疗的抗中性粒细胞胞浆抗体相关性血管炎患者中评估C5a受体抑制剂阿伐库潘的安全性和有效性：一项随机、双盲、活性对照3期试验方案
JMIR Res Protoc. 2020 Apr 7;9(4):e16664. doi: 10.2196/16664.
5
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.C5a受体抑制剂阿伐库潘治疗抗中性粒细胞胞浆抗体相关性血管炎的随机试验
J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.
6
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.口服C5a受体抑制剂阿伐考泮辅助治疗抗中性粒细胞胞浆抗体相关性血管炎患者。
ACR Open Rheumatol. 2020 Nov;2(11):662-671. doi: 10.1002/acr2.11185. Epub 2020 Oct 31.
7
Avacopan: First Approval.阿伐考潘：首次获批
Drugs. 2022 Jan;82(1):79-85. doi: 10.1007/s40265-021-01643-6.
8
Avacopan for the treatment of ANCA-associated vasculitis.阿伐考潘治疗抗中性粒细胞胞质抗体相关性血管炎。
Expert Rev Clin Immunol. 2021 Jul;17(7):717-726. doi: 10.1080/1744666X.2021.1932466. Epub 2021 May 28.
9
In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission.在抗中性粒细胞胞浆抗体相关性血管炎中，阿伐考帕尼优于泼尼松减量维持缓解。
Ann Intern Med. 2021 Jul;174(7):JC79. doi: 10.7326/ACPJ202107200-079. Epub 2021 Jul 6.
10
Complement Inhibition in ANCA-Associated Vasculitis.补体抑制在抗中性粒细胞胞浆抗体相关性血管炎中的作用。
Front Immunol. 2022 Jul 8;13:888816. doi: 10.3389/fimmu.2022.888816. eCollection 2022.
引用本文的文献
1
Complement Cascades and Brain Disorders.补体级联反应与脑部疾病
Biomolecules. 2025 Aug 17;15(8):1179. doi: 10.3390/biom15081179.
2
Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy.评估阿伐库潘治疗抗中性粒细胞胞浆抗体相关性血管炎：治疗方案的设计、研发与定位
Drug Des Devel Ther. 2025 Jan 4;19:23-37. doi: 10.2147/DDDT.S341842. eCollection 2025.
3
Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities.儿童肾脏疾病中的补体抑制剂：新的治疗机遇
Pediatr Nephrol. 2024 May;39(5):1387-1404. doi: 10.1007/s00467-023-06120-8. Epub 2023 Sep 21.
4
Combination Treatment of Locoregionally Aggressive Granulomatosis with Polyangiitis and Cranial Base Infiltration.局限性侵袭性肉芽肿性多血管炎合并颅底浸润的联合治疗
Brain Sci. 2023 Jul 29;13(8):1140. doi: 10.3390/brainsci13081140.
本文引用的文献
1
Avacopan as First-Line Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Steroid-Sparing Option.阿伐库潘作为抗中性粒细胞胞浆抗体相关性血管炎的一线治疗：一种节省类固醇的选择。
Kidney Int Rep. 2022 Jan 30;7(5):1115-1118. doi: 10.1016/j.ekir.2022.01.1065. eCollection 2022 May.
2
Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.阿伐可泮在难治性抗中性粒细胞胞浆抗体相关性血管炎中的同情用药
Kidney Int Rep. 2021 Dec 8;7(3):624-628. doi: 10.1016/j.ekir.2021.11.036. eCollection 2022 Mar.
3
Avacopan for the Treatment of ANCA-Associated Vasculitis.阿伐考潘治疗抗中性粒细胞胞浆抗体相关性血管炎。
N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386.
4
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.口服C5a受体抑制剂阿伐考泮辅助治疗抗中性粒细胞胞浆抗体相关性血管炎患者。
ACR Open Rheumatol. 2020 Nov;2(11):662-671. doi: 10.1002/acr2.11185. Epub 2020 Oct 31.
5
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.C5a受体抑制剂阿伐库潘治疗抗中性粒细胞胞浆抗体相关性血管炎的随机试验
J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.
6
ANCA-associated vasculitis.抗中性粒细胞胞浆抗体相关性血管炎
Clin Med (Lond). 2017 Feb;17(1):60-64. doi: 10.7861/clinmedicine.17-1-60.
Zotero 插件